Zacks Investment Research downgraded shares of UCB (NASDAQ:UCBJF) from a buy rating to a hold rating in a report released on Friday morning.
According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “
Shares of UCB (NASDAQ:UCBJF) opened at 70.00 on Friday. The stock has a market cap of $13.21 billion and a P/E ratio of 23.27. UCB has a 12 month low of $58.42 and a 12 month high of $86.75. The stock’s 50 day moving average is $78.51 and its 200 day moving average is $70.72.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.